Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (59)	3/2/2017 10:24:16 AM
From: Biotech Jim	1 Recommendation Recommended By The Ox Respond to of 84

Done buying JUNO shares for now, that was a huge no-brainer. Biotechs blow out on bad news, but those who know the pipeline and potential will look back on this as the weak hands shareholder blowout. I waited a long time to get my price, years and minutes both. I am going to step out on the limb here and suggest that we may close positive.

To: Biotech Jim who wrote (59)	3/2/2017 10:30:19 AM
From: tuck	2 Recommendations Recommended By Biotech Jim The Ox Read Replies (1) \| Respond to of 84

Parking the Juno and Kite pipelines here so followers can compare. Kite Pipe Juno Pipe (note Juno's pipe isn't confined to one web page, but this has the clinical stuff) A lot to check out, at both Juno and Kite. Many of the same indications addressed, but after CD19, basically no overlap in targets. Kite has a different approach to solid tumors, for example, using TCRs and different targets (though I see Juno also uses a TCR against WT-1). Sold some puts this morning. Didn't get top dollar, but off to a good start. You haven't talked much about which programs you think have the best chances, but I'm sure you have an opinion. Currently, 017 seems to be addressing a smaller market; I don't now now what populations they're enrolling in the pediatric trial. Do you have a favorite in the remaining two CD19 programs? Cheers, Tuck